<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>SUMMARY: <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">Moyamoya</z:e> is a cerebral vasculopathy of unknown etiology rarely described as a late effect after the treatment of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We describe a 12-year-old female who developed <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya</z:e> after the completion of systemic chemotherapy, surgery, and adjuvant interferon alpha for <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> with <z:e sem="disease" ids="C0153676" disease_type="Neoplastic Process" abbrv="">pulmonary metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Given the importance of characterizing late effects after the treatment of <z:e sem="disease" ids="C0278704" disease_type="Neoplastic Process" abbrv="">childhood cancer</z:e>, the potential role of interferon alpha in the development of <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">moyamoya</z:e> is discussed </plain></SENT>
</text></document>